

()
 .()
 (VEGF)³ ()
 () RNA DNA .()
 ()
 () Tetrahymena Thermophila
 ()
 () RNA
 hTR¹ DNA ()
 hTERT²
 hTR .()
 (T47D) .() hTR mRNA
 hTERT .()
 hTERT .()
 :
 :
 Sigma (Seleno-L-methionine) .(-)
 (ZnSo4) (S) .()
 Merck (CuSo4)
 () () .()
 () T47D MZF₂¹
 (Growing) NCBI : C203 APA1²
 .()
 (Dulbecco's modified Eagle's medium)DMEM DNA
 (A) AppliChem .()
) Telo TAGGG Telomerase PCR ELISA^{plus} C
 Roche (

³ Vessel Endothelial Growth Factor

¹ human telomerase RNA
² human telomerase enzyme reverse transcriptase(hTERT)
¹ Motif Zinc Finger

(BSA)

Dulbecco's)DMEM

T47D

(modified Eagle's medium

(fetal bovine serum)

G)

OD Ultraspec2000

(

OD

TRAP Assay

,TRAP Assay

T47D

) Telo TAGGG Telomerase PCR ELISA^{plus}

Roche (

/ /

PCR

()

) Primer elongation

(

()

()

Telomerase Inactivation

(Amplification) PCR

Denaturation : PCR ()

Annealing

Polymerization

(Amplification)

,TRAP

Assay

PCR

Polymerization

TRAP Assay

PCR

ELISA

/

Hybridization buffer T

PCR

Hybridization buffer IS

()

Bio-Rad

MTB

()

Anti-
)
 (

Washing buffer
 DIG-HRP working solution

Washing buffer

substrate solution TMB

Stop Reagent


ELISA Reader (Stat Fax 2100, USA)

:

)

) (

Fold increased (



TRAP Assay

Fold) (increased	T47D		(RTA)	
	%RTA Mean	()	()	
/	/			
/	/			
/	/			()
/	/			
/	/			
/	/			()
/	/			
/	/			()
/	/			

C- DNA

Bae SV.)MYC T47D

() (/

Nemato k.

Choriocarcinoma

(NPT) :

(HT) /

(Bewo) Choriocarcinoma

/

/

(Bewo)

/

E2F p21

p53

E2F p21

p53

()

()

/ T47D

/

/

/

/

Nemato k

Bae SV.

()

/ /

/ /

/

G2/M

G0/G1

()

()

ATP

bFGF TNF- α (VEGF)

C

C

dATP

Caspase-12

Caspase-3

()

() Bax

() Bcl-2

Bax

2 Bcl-

/

p21

p53

(hTERT)

Chen WX.

()

E2F p21

p53

Nemato k.

()

() Rap1p

) C-MYC

() P53 (

DNA ()

DNA

in vitro

DNA

()

(Switch Off)

()

Lio Q.

L02

/ /

()

Cui QH.

7- Reference:

1. olcatova B. Environmental epidemiology of malignancies: The natural European perspective, *Centr.eur.J.publ.Hlt.*, 1998, 6(1): 13-17.
2. ankey. Cancer statistics review 1973-1989, NIH, pub., 1992, 2789 (92): 1-17
3. ohagheghi MA., Musavi-Jarrahi A., Torbaghan S. Annual report of: Tehran university of medical sciences district cancer registry (TUMS-DCR).The cancer institute publication, 1999, 7: 43.
4. Greider C.W, Blackburn A. B, Blackburn E. H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts, *Cell*, 1985, 43: 405-413.
5. Kim N.W, Piatyszek M. A, Prowse K. R, Harley C. B, West M. D, Ho P. L, et al. Specific association of human telomerase activity with immortal cells and cancer, *Science*, 1994, 266: 2011-2015.
6. Shay J. W, Wright W. E, Hayflick. his limit, and cellular aging. *Nat Rev Mol Cell Biol*, 2000, 1: 72-76.
7. Feng J, Funk W. D, Wang S .S, Weinrich S. L, Avilion A .A, Chiu C. P, et al. The RNA component of human telomerase. *Science*, 1995, 269:1236-1241.
8. Kilian A, Bowtell D. D, Abud H. E, Hime G. R, Venter D. J, Keese P. K, et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types, *Hum Mol Genet.* 1997, 6: 2011-2019.
9. Lingner J, Hughes T.R, Shevchenko A, Mann M,Lundblad V, Cech T.R. Reverse transcriptase motifs in the catalytic subunit of telomerase, *Science*, 1997, 276: 561-567.
10. Meyerson M, Counter C. M, Eaton E. N, Ellisen L. W, Steiner P, Caddle S. D. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization, *Cell*, 1997, 90: 785-795.
11. Avilion A .A, Piatyszek M. A, Gupta J, Shay J .W, Bacchetti S,Greider C. W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues, *Cancer Res*, 1996, 56: 645-650.
- 12.Yi X, Tesmer V. M, Savre-Train I, Shay J. W,Wright W. E. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels, *Mol Cell Biol*, 1996, 19: 3989-3997
13. Nemoto K, Kondo Y, Himeno S, Suzuki Y, Hara S, Akimoto M. Modulation of Telomerase activity by zinc in human prostatic and renal cancer cells, *Biochem Pharma.*, 2000, 59(4): 401-405.
14. Powell RS. The antioxidant properties of Zinc, *J Nutr.*, 2000, 130: 1447-54
15. Benanti JA, Williams DK, Robinson KL, Ozer HL, Galloway DA. Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1, *Mol Cell Biol*, 2002, 22(21): 7385-97.
- 16.Qiang Liu. Zinc Finger Proteins To Study Breast Cancer Angiogenesis, *Proc Natl Acad Sci U S A.*, 1997, 94(11): 5525-30.
17. Brewer JG. Copper Control As An Antiangiogenic Anticancer Therapy: Lessons From Treating Wilson' S Disease, *Exp Biol Med (Maywood)*, 2001, 226(7): 665-73.

-
18. Kim SY, Kim JW, Ko YS, Koo JE, Chung HY, Lee-Kim YC. Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer. *Nutr Cancer*, 2003, 47(2): 126-30
 19. Karunasinghe N, Ferguson LR, Tuckey J, Masters J. Hemolysate thioredoxin reductase and glutathione peroxidase activities correlate with serum selenium in a group of New Zealand men at high prostate cancer risk. *J Nutr.*, 2006, 136(8): 2232-5.
 20. Cavallo F, Gerber M, Marubini E, Richardson S, Barbieri A, Costa A, et al. Zinc and copper in breast cancer. A joint study in northern Italy and southern France. *Cancer*, 1991, 67(3): 738-45.
 21. Chen WX, Cao XZ, Zhu RZ. Effect of selenium dioxide on proliferation, apoptosis, and telomerase activity of human lung cancer cell line in vitro. *Ai Zheng.*, 2003, 22(9): 927-31.
 22. M. Sanz Alaejos, F. J. D'az Romero, and C. D'az Romero. . Selenium and Cancer. *Some Nutritional Aspects, Nutrition*, 2000, 16: 376 –383.
 - 23- Bae S. N. Lee Y. S., Kim M.Y., Kim J. D, Park., L .O. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR®) on human epithelial ovarian cancer cell line, OVCAR-3, *Gynecol Oncol.*, 2006, 103(1): 127-36.
 - 24- Bae SN, Kim J, Lee YS, Kim JD, Kim MY, Park LO. Cytotoxic effect of zinc-citrate compound on choriocarcinoma cell lines. *Placenta*, 2007, 28(1): 22-30.
 - 25- Nelson RL, Davis FG, Sutter E, Kikendall JW, Sobin LH, Milner JA, et al. Serum selenium and colonic neoplastic risk, *Dis. Colon Rectum* 1995, 38: 1306-1310.
 26. Piccinini L, Borella P, Bargellini A, Medici CI, Zoboli A. A Case -control study on selenium, zinc, and copper in plasma and hair of subjects affected by breast and lung cancer, *Biol Trace Element Res.*, 1996 51(1): 23-30.
 - 27- Chen HJ, Yu RA, Wu ZG, Xia T, Yang CF, Yang KD, et al. Effects of selenium on expression of TERT, c-Myc and p53 induced by cadmium in rat liver, *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi*, 2006, 24(1): 35-8.
 - 28- Davis CD, Uthus EO. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats, *J Nutr.*, 2003 133(9): 2907-14.
 - 29- Liu Q, Wang H, Hu DC, Ding CJ, Xiao H, Xu HB, et al. Effects of sodium selenite on telomerase activity and telomere length, *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai).*, 2003, 35(12): 1117-22.
 - 30- Kuo HW, Chen SF, Wu CC, Chen DR, Lee JH. Serum and tissue trace elements in patients with breast cancer in Taiwan, *Biol Trace Elem Res.*, 2002, 89(1): 1-11.

Archive of SID